Drugs / GLP-1(7-36)
GLP-1(7-36)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01507597 | Dec 2011 → Aug 2013 | type 1 diabetes mellitus, type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLP-1(7-36) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01507597 ↗ |
| Known as | GLP-1 | “Native human Glucagon-like Peptide-1 ( GLP-1(7-36))” NCT01507597 ↗ |
| Known as | Glucagon-like Peptide-1 | “Native human Glucagon-like Peptide-1 ( GLP-1(7-36))” NCT01507597 ↗ |
| Action | Inhibit | “glucagon-like peptide 1 (GLP-1) suppresses glucagon secretion.” PMID 33722838 ↗ Mar 2021 |
| Route | Intravenous | “Continuous iv. infusion of the native gut hormone GLP-1” NCT01507597 ↗ |